Heidelberg Pharma AG (HPHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heidelberg Pharma AG (HPHA) has a cash flow conversion efficiency ratio of -0.299x as of May 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.53 Million ≈ $-6.46 Million USD) by net assets (€18.52 Million ≈ $21.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HPHA market cap overview for the company's overall valuation and market capitalisation.
Heidelberg Pharma AG - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Heidelberg Pharma AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Heidelberg Pharma AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heidelberg Pharma AG ranked by their cash flow conversion efficiency. Explore Heidelberg Pharma AG earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ADC Therapeutics SA
NYSE:ADCT
|
0.137x |
|
Inclusio Sca
BR:INCLU
|
0.002x |
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
-0.016x |
|
Leoch International Technology Limited
F:0LT
|
-0.006x |
|
General de Alquiler de Maquinaria SA
MC:GAM
|
0.367x |
|
GR Silver Mining Ltd
V:GRSL
|
-0.043x |
|
Schwager
SN:SCHWAGER
|
0.113x |
|
LEWAG Holding Aktiengesellschaft
F:KGR
|
-0.084x |
Annual Cash Flow Conversion Efficiency for Heidelberg Pharma AG (2016–2024)
The table below shows the annual cash flow conversion efficiency of Heidelberg Pharma AG from 2016 to 2024. View HPHA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | €30.87 Million ≈ $36.09 Million |
€-29.59 Million ≈ $-34.59 Million |
-0.959x | -40.46% |
| 2023-11-30 | €49.34 Million ≈ $57.68 Million |
€-33.67 Million ≈ $-39.37 Million |
-0.682x | -413.10% |
| 2022-11-30 | €66.64 Million ≈ $77.91 Million |
€-8.86 Million ≈ $-10.36 Million |
-0.133x | +96.65% |
| 2021-11-30 | €6.70 Million ≈ $7.83 Million |
€-26.61 Million ≈ $-31.11 Million |
-3.973x | -185.96% |
| 2020-11-30 | €12.88 Million ≈ $15.06 Million |
€-17.89 Million ≈ $-20.92 Million |
-1.389x | -164.54% |
| 2019-11-30 | €16.29 Million ≈ $19.05 Million |
€-8.56 Million ≈ $-10.00 Million |
-0.525x | -36.17% |
| 2018-11-30 | €25.89 Million ≈ $30.26 Million |
€-9.98 Million ≈ $-11.67 Million |
-0.386x | -79.83% |
| 2017-11-30 | €37.02 Million ≈ $43.28 Million |
€-7.94 Million ≈ $-9.28 Million |
-0.214x | +67.98% |
| 2016-11-30 | €9.76 Million ≈ $11.41 Million |
€-6.53 Million ≈ $-7.64 Million |
-0.670x | -- |
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more